. Characteristic features of the nanoparticle concept based on recombinant TR3 variants tethered to mouse RBCs. (a) The scFv-Ter119 [yellow ovals] was fused to the N-terminus of TR3 (blue ovals) without (left, Ter119-TR3) and with an elongated spacer (right, Ter119-S-TR3). The spacer was derived from the globular domains of human CR1 and DAF (see Materials and Methods for details and ref. 33) . Immunologic detection on mouse RBCs was performed using soluble DR5-Fc (orange/grey). (b) The relative abundance of the spacerdeficient Ter119-TR3 (red line) was~1.7-fold higher than the spacer-containing Ter119-S-TR3 (green line). (c) Functional activity of the same RBC preparations shown in (b) using a coculture assay with human Jurkat cells at increasing effector:target cell ratios (E/T) as described 8. Mouse RBCs incubated with medium alone served as a control. (d) Mouse RBCs coated with Ter119-TR3 and Ter119-S-TR3 (compare (b) for coating levels) were treated at increasing effector ratios with Jurkat cells either with (dashed lines) and without transwell separation (solid lines). Non-coated RBCs served as a control. Cell death was determined by FACS analysis as described 8 . Target cell killing was nearly completely abrogated when cell-cell contact was inhibited (dashed red line). (b) HEK293T cells were transiently transfected with a recombinant, signaling-deficient form of human vascular endothelial growth factor receptor-2 (VEGFR-2, KDRdCYT-eYFP). The cells were stained the following day with an anti-KDR mAb and submitted to FACS analysis. The resulting expression pattern is characteristic for a proportional relationship between the YFP marker and the surface receptor (KDR-YFP, diagonal arrow), which is maintained over the entire expression range and documents unrestricted accessibility of the detection reagent to its binding epitope of the surface antigen. a b Fig. S6 . Transmembrane and GPI-anchored TR3 variants display equivalent staining profiles in DR5expressing mammalian cells. In order to assess the phenotypic characteristics of membrane anchorage of recombinant TR3, DR5-positive HEK293T cells were transiently transfected with the bicistronic expression plasmids TR3-GPI and TR3-TM (compare Fig. S5 for specifics about plasmid design). The next day, the cells were prepared for flow cytometry using the blocking anti-TRAIL detection antibody 2E5. The primary antibody was visualized with a PE-conjugated secondary antibody. Please note that the expression profiles of TR3-GPI and TR3-TM are equivalent and result in a diagonal pattern (proportional relationship between TR3 and the YFP marker), similar to the expression profile of wt TRAIL (Fig. 5c ).
